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ABSTRACT
Identifying the true prevalence of human T-cell lymphotropic virus, mostly type 1 
(HTLV-1), and the number of patients with HTLV-1-associated diseases, in addition to 
introducing HTLV-1/2 serology during the prenatal of pregnant women and in individuals 
infected with other viruses that share transmission routes with HTLV-1, are actions that could 
help to recognize the importance of this virus by WHO and national health organizations, 
and to control its transmission/dissemination. As Brazil is endemic to HTLV and there is an 
increase in health care expenditure, but resources are limited, any strategy that could reduce 
the cost of HTLV screening is needed and welcomed. This study aimed to determine whether 
the strategy of pooling sera for HTLV antibody determination is feasible and reduces the 
costs. Two enzyme immunoassays (EIA Murex HTLV-I+II, Diasorin, UK, and Gold ELISA 
HTLV-1+2, REM Ind. Com. Ltda., SP, Brazil), and serum samples that resulted in different 
levels of HTLV-1/2 antibodies by EIA and of which a volume allowed assay validation were 
employed for analysis. The diagnostic sensitivity and specificity and Cohen’s Kappa value, 
as well as the accuracy and precision were analyzed. After validating the five-sample pool 
using the EIA Murex (Cohen’s Kappa = 1.0), the technique was employed for individual 
cost comparison in 2,625 serum samples from populations at risk of HTLV infections 
(HBV, HCV, and HIV-infected individuals). The results from individual and pooled samples 
confirmed the diagnostic sensitivity (100%) and specificity (100%) of the pooling and a cost 
minimization varying from 60.7% to 73.6%. In conclusion, the results of this study suggest 
the use of pooling sera in sero-epidemiological surveillance studies and possibly in prenatal 
care screening programs in Brazil.
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INTRODUCTION
In recent years, several attempts have been made to persuade the World Health 
Organization (WHO) and other local health organizations to include human T-cell 
lymphotropic virus, primarily type 1 (HTLV-1) and associated diseases, in the list 
of neglected pathogens/infectious diseases1-4. This is due to the high number of 
HTLV-infected individuals worldwide1,5, as well the high mortality and morbidity 
of HTLV-1-associated diseases, such as adult T-cell leukemia/lymphoma (ATLL) 
and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)1-6.
Identifying the true prevalence of HTLV-1-infected individuals and the number 
of patients with HTLV-1-associated diseases is one way to highlight the importance 
of this neglected human retrovirus1,2,4,6. Currently, introducing HTLV-1/2 serology 
in prenatal care for pregnant women to avoid breastfeeding transmission4,6,7, 
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in individuals infected with other viruses that share 
transmission routes with HTLV-1/28-10, and including HTLV 
in the National Mandatory Notification List are actions to 
control HTLV transmission/dissemination in Brazil and 
worldwide2,4,10. As Brazil is endemic to HTLV-1/25 and at 
a time in which there is increasing health care expenditure, 
but resources are limited, any strategy that could reduce the 
cost of HTLV screening is needed and welcomed. Indeed, 
since HTLV-1 and HTLV-2 have different pathogenicity, 
discriminating HTLV-1 from HTLV-2 is important for a 
better follow-up of infected individuals11.
Several years ago, the strategy based on pooling of 
samples was shown to be feasible for large-scale sero-
epidemiological studies in HIV12,13, and more recently 
in HTLV14,15. By using samples from various population 
groups and enzyme-linked immunosorbent assays (ELISAs) 
for screening, the strategy saves resources in terms of labor 
and test reagents12-15.
Although there are several methods for the health 
economic evaluation that consider both, cost and 
consequences, such as cost minimization, cost effectiveness, 
cost utility, cost benefit, and other economic modeling, 
cost minimization seems to be appropriate for comparing 
individual samples and pooled samples in screening when 
it is assumed that the final result is the same16.
Based on the above mentioned information and the fact 
that the pooling of serum samples has not been employed 
for HTLV screening in Brazil, we decided to conduct the 
present study, to ascertain the feasibility of this strategy 
for detecting antibodies to HTLV-1, HTLV-2 and HTLV 
untypeable truly positive samples in populations at risk.
MATERIALS AND METHODS
Samples and assays
Firstly, 81 serum samples from a biorepository that 
resulted in HTLV-1-, HTLV-2- or HTLV-positive but 
untypeable serological assays were reanalyzed by two 
enzyme immunoassays (EIAs) commonly used for 
screening in public health laboratories in Brazil (EIA Murex 
HTLV-I+II, Diasorin, UK, and Gold ELISA HTLV-1+2, 
REM Ind. Com. Ltda., SP, Brazil), and the reactions and 
interpretation of results were conducted according to the 
respective manufacturers’ instructions. Briefly, these assays 
are sandwich enzyme immune assays with recombinant 
antigens and synthetic peptides capable of detecting all the 
classes of HTLV-1- and HTLV-2-specific antibodies. The 
optical density-to-cut off ratio (OD/CO) was determined 
and considered reactive when OD/CO was >1.0. Samples 
with 1.1 ≤ OD/CO ≥ 0.9 were considered borderline or in the 
gray zone (10% ± CO) for HTLV-1/2 antibodies. Notably, 
samples considered reactive and borderline on screening 
were tested by Western blot (WB, HTLV BLOT 2.4, MP 
Biomedicals Asia Pacific Pte Ltd., Genelabs) and line 
immunoassay (LIA, INNO-LIA HTLV-I/II Score, Fujirebio, 
Europe N. V, Belgium) for confirming HTLV positivity. The 
reactions and criteria for interpretation of the serological 
confirmatory results (bands) were made according to the 
manufacturers’ instructions and are described in detail 
elsewhere17.
Samples that presented the lowest reactivity and highest 
reactivity results in both EIA screening assays, of which the 
volume was sufficient for testing and validating the pooling 
strategy, were employed for analysis.
Initially, to ascertain the feasibility of the use of the 
pooling in screening, five serum samples, two HTLV-1 
(one of low and one of high OD/CO value), two HTLV-2 
(one of low and one of high OD/CO value), and one HTLV 
(high OD/CO value), were diluted in two steps; firstly, in 
serum from a negative blood bag for infectious blood-borne 
diseases using serial dilution starting in 1/2, 1/4, 1/8, 1/16, 
1/32, 1/64 and interposing the dilution 1/5, 1/10 and 1/20; 
samples that continued HTLV reactive at 1/64 were diluted 
until the end point titration. Subsequently, after knowing 
the highest serum dilution without loss of reactivity in 
both EIAs and deciding which one was more suitable to 
be used in the pool, the samples were diluted in different 
positive and negative HIV, HBV and HCV serum samples 
to ensure that these infectious agents would not interfere 
in the pooling strategy.
Afterwards, samples containing sufficient volume for 
the diagnostic method validation assays were selected 
and tested for the pooling strategy using the guideline 
established by the Instituto Adolfo Lutz (P-SG-0022 
Validação de métodos de ensaio de diagnóstico), which 
agrees with a protocol described in the literature18. Forty 
pools were employed for accuracy analysis (35 containing 
serum samples from HTLV-1, HTLV-2 or HTLV seropositive 
patients, and five containing samples from healthy control 
individuals, negative for HTLV-1/2), tested only once and 
for five consecutive days, along with up to seven pools for 
the precision analysis (five containing serum samples from 
HTLV-1, HTLV-2 or HTLV-positive patients, and two from 
negative controls). The intra-assay (repeatability) of the 
pooling was conducted in triplicate over five consecutive 
days, and the inter-assay (reproducibility) in duplicate 
performed by three analysts. Of note, all the pools were 
prepared at the same time, divided into aliquots, and 
stored at 4 °C (refrigerator) until use (maximum five days). 
Figure 1 presents the flowchart of the steps and the samples 
employed in the study.
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Finally, for calculating the diagnostic sensitivity and 
specificity and the cost minimization of the HTLV-1/2 
screening using individual samples and pooled samples, 
2,000 serum/plasma samples from patients with viral 
hepatitis B and C and 625 plasma samples from patients 
with HIV/AIDS that had been individually screened using 
the same EIA, of which the results had been published 
elsewhere19,20, were employed. The cost minimization 
in percentage was calculated considering the value in 
American dollars (U$ 1.5 per reaction) in the EIA acquired 
in 2019.
Statistical analysis
The laboratory results were recorded and analyzed 
using Epi Info version 3.5.4 software (CDC, Atlanta, GA, 
USA). For validation, the accuracy of the pooling assay 
was assured by determining the diagnostic sensitivity and 
Figure 1 - Flowchart of the steps and the samples employed in the human T-cell lymphotropic virus (HTLV) screening, using the 
pooling of sera strategy. H = high reactive sample by EIA; L = low reactive sample by EIA.
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specificity and Cohen’s Kappa value. GraphPad Prism 
version 5.00 [Trial] software (GraphPad Software, San 
Diego, CA, USA), was employed for precision analysis 
(repeatability and reproducibility) by calculating the mean 
OD/CO value, standard deviation (SD), and coefficient of 
variation in percentage (CV). The total values of mean, SD 
and CV were calculated considering the values obtained in 
each reaction. 
RESULTS
Table 1 presents the results of OD/CO obtained in serum 
samples with low and high HTLV-1/2 antibody titers when 
individually analyzed by Murex and Gold ELISA and after 
serial dilution in normal HTLV-negative plasma. They 
disclosed that the highest serum dilutions without loss of 
reactivity in samples with low OD/CO results were 1/5 
(Murex) and 1/2 (Gold ELISA), independent of HTLV-1 
or HTLV-2 infection (Table 1, in bold).
After establishing the highest dilution (1/5) without loss 
of reactivity for any type of sample (HTLV-1, HTLV-2 or 
HTLV low or high positives) and the better EIA for use in 
the pool (Murex), the lack of interference or cross-reactivity 
of the pooling assays was confirmed using plasma samples 
of different infected individuals (HIV, HBV and HCV) and 
negative controls (Table 2).
When 40 pools of sera were tested, the accuracy of the 
pooling was confirmed, although on day five, one pool 
containing one HTLV-1 low reactive serum sample resulted 
in a borderline result in the EIA (Figure 2).
Briefly, the repeatability of the pooling was confirmed 
disclosing coefficient of variations (CV) ranging from 
6.46% to 16.13%. The pool that presented the highest CV 
was the one containing an HTLV-2 low reactive sample 
(Table 3).
Concisely, the reproducibility of the pooling assay 
by three analysts was 100%; generating no false-positive 
or false-negative result. The total CV values in pools 
containing HTLV-1-, HTLV-2- and HTLV-positive serum 
samples ranged from 4.74% to 8.37%, and the highest 
CV (17.70%) was detected in a pool containing only 
HTLV-negative samples (Table 4).
After validating the five-sample pool using EIA Murex, 
the technique was employed for individual cost comparison 
in 2,625 serum samples previously screened, of which the 
final HTLV confirmatory results were published elsewhere: 
1,300 from patients with hepatitis B, 700 with hepatitis C, 
and 625 with HIV/AIDS19,20. The results from individual 
and pooled samples confirmed the diagnostic sensitivity 
(100%) and specificity (100%) of the pooling (Cohen’s 
Kappa = 1.0), and a cost minimization of 70.4%, 60.7% 
and 73.6% in these populations (Figure 3), depending on 
Table 1 - Major serum dilution capable of detecting HTLV-1/2 truly positive samples using two enzyme immunoassays.
Sample
Murex Gold ELISA Murex Gold ELISA
OD/CO OD/CO Dilution* OD/CO Dilution* OD/CO
HTLV-1 (H) 13.35 >9.6 1/65,536 1.59 1/8,192 1.93
HTLV-1 (L) 6.7 3.7 1/5 1.14 1/4 1.89
HTLV-2 (H) 13.41 9.6 1/16,384 1.04 1/2,048 1.06
HTLV-2 (L) 7.15 2.1 1/10 1.02 1/2 1.03
HTLV (H) 12.94 8.6 1/128 1.77 1/32 1.81
Murex and Gold ELISA assays according to the manufacturer’s instructions; *Serum sample dilution in blood donor bags negative 
for all blood-borne infectious agents; OD/CO = optical density-to-cut off ratio; H = high reactive sample by EIA; L = low reactive 
sample by EIA. In bold, the highest serum dilutions without loss of reactivity in low reactive samples.
Table 2 - HTLV-1/2 optical density-to-cut off values of high and low reactive serum samples when pooled in samples from individuals 
infected and uninfected with HIV, HBV and HCV using EIA Murex.
Sample Individual sample HIV* HBV* HCV* Negative**
HTLV-1 (H) 13.35 13.08 13.11 13.22 13.11
HTLV-1 (L) 6.7 1.48 1.53 2.09 1.86
HTLV-2 (H) 13.41 13.05 13.02 13.24 13.21
HTLV-2 (L) 7.15 2.43 2.13 2.83 2.21
HTLV (H) 12.94 12.46 11.8 12.45 11.33
H = high reactive samples by Murex; L = low reactive sample by Murex; *pool of five sera samples (one infected with HTLV and four 
infected with HIV or HBV or HCV); **pool of five sera samples (one infected with HTLV and four uninfected with HIV, HBV and HCV).
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the prevalence of HTLV-1/2 (1.9% in HBV, 4.0% in HCV, 
and 1.1% in patients with HIV/AIDS)19,20.
Briefly, the 1,330 HBV positive serum samples were 
grouped into 260 pools; HTLV-1/2 screening disclosed 
25 HTLV-positive pools. When the sera that composed 
these 25 pools were analyzed separately (n=125), one 
pool had two positive samples; the same 26 samples were 
detected in individual analysis20. A cost minimization of 
70.4% would have been achieved if this strategy had been 
employed (total of 385 reactions instead of 1,330 reactions, 
Figure 3A). The same calculation was employed in HCV: 
the 700 HCV positive serum samples were grouped in 
140 pools; 27 were positive by EIA, and when the sera that 
formed the 27 positive pools were analyzed individually, 
two pools presented two positive samples; the same 
samples were detected in previous individual analysis20. 
For calculating the cost minimization, 140 reactions tested 
in pool plus 135 tested individually, totaling 275 reactions 
instead of 700 reactions, with a cost minimization of 
60.7% (Figure 3B). Finally, the 625 positive serum samples 
of HIV/AIDS were grouped into 125 pools; eight were 
EIA positive; therefore, 125 reactions plus 40 reactions, 
total of 165 reactions instead of 625 reactions, with a 
cost minimization of 73.6% (Figure 3C). Of note, in 
HIV/AIDS, one of the eight reactive pools was capable of 
detecting a borderline OD/CO sample identified previously 
in individual analysis, and this sample did not confirm 
HTLV-1/2 infection by Western Blot and INNO-LIA19.
DISCUSSION
In recent years, several attempts have been made to 
make HTLV-1 infection and associated diseases visible 
worldwide and in Brazil1-4. One of the means to achieve 
this goal is to know the real prevalence of the infection 
and associated diseases in the general population and 
in individuals who could acquire/transmit this infection 
more easily, such as individuals infected with other 
microorganisms that share routes of transmission with 
HTLV-18,9,19,20 and HTLV-1-infected mothers who could 
transmit the virus to their infants during breastfeeding4,6,7. 
In Brazil, the estimated number of HTLV-1-infected 
Figure 2 - Accuracy of the pooling strategy: comparison of the 
optical density-to-cut off (OD/CO) values obtained in 40 pools 
containing sera which were tested individually and in pools, and 
that ascertain the feasibility of the pooling strategy in HTLV-1/2 
antibody screening using EIA Murex. Light green dots = pools of 
sera containing samples with low levels of HTLV-1 antibodies; 
dark green dots = pools of sera containing samples with high 
levels of HTLV-1 antibodies; light red dots = pools of sera 
containing samples with low levels of HTLV-2 antibodies; dark 
red dots = pools of sera containing samples with high levels of 
HTLV-2 antibodies; light brown dots = pools of sera containing 
samples with high levels of HTLV antibodies; gray dots = pools 
of sera containing samples negative for HTLV antibodies. 
H = high reactive sample by EIA; L = low reactive sample by 
EIA. Composition of pools according to Materials and Methods.
Table 3 - Intra-assay results (repeatability) of HTLV-1/2 antibody determination in triplicate over five consecutive days using EIA 
Murex and pool of five serum samples with different compositions.
ID Pool Sample
OD/CO
Individual MeanD1 SDD1 CVD1% MeanD2 SDD2 CVD2% MeanD3 SDD3 CVD3% MeanD4 SDD4 CVD4% MeanD5 SDD5 CVD5% MeanT SDT CVT%
P-09a HTLV-1 [L1] 5.36 1.36 0.05 3.95 1.54 0.05 3.01 1.40 0.08 5.93 1.38 0.09 6.36 1.19 0.08 6.60 1.37 0.13 9.55
P-14a HTLV-1 [L2] 6.54 1.76 0.09 5.32 1.89 0.06 3.30 1.73 0.06 3.19 1.72 0.04 2.26 1.58 0.03 1.60 1.74 0.12 6.70
P-19a HTLV 12.79 11.93 0.24 2.01 10.83 0.17 1.61 10.26 0.04 0.42 10.41 0.04 0.53 10.12 0.11 1.12 10.71 0.69 6.46
P-24a Negative 0.23 0.22 0.01 3.64 0.23 0.03 13.08 0.23 0.03 14.87 0.26 0.03 10.69 0.26 0.01 5.48 0.24 0.03 11.44
P-25b Negative 0.23 0.23 0.03 12.28 0.21 0.02 7.39 0.23 0.04 16.06 0.22 0.01 3.83 0.21 0.01 2.65 0.22 0.02 9.51
P-34a HTLV-2 [L1] 6.58 1.57 0.02 1.25 1.50 0.16 10.47 1.54 0.03 1.65 1.43 0.04 3.13 1.25 0.01 0.99 1.46 0.13 9.22
P-39a HTLV-2 [L2] 5.6 1.71 0.09 5.23 1.61 0.06 3.49 1.81 0.17 9.42 1.52 0.21 14.01 1.17 0.05 4.42 1.56 0.25 16.13
ID = Pool sera identification; OD/CO = optical density-to-cut off ratio; SD = standard deviation; CV = coefficient of variation; L = low reagent samples by Murex; D = day of sample 
testing (D1, 1
st day; D2, 2
nd day; D3, 3
rd day; D4, 4
th day; D5, 5
th day); T = total results. Pool composition: 
afour samples HIV/HBV/HCV/HTLV-seronegative; bmix of one HIV-, one HBV-, and 
one HCV-positive samples plus one HIV/HBV/HCV/HTLV-negative sample. GraphPad Prism version 5.00 [Trial] software (GraphPad Software, San Diego, CA, USA) was employed by 
calculating the mean OD/CO, SD, and CV values.
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Table 4 - Inter-assay results (reproducibility) of HTLV-1/2 antibody determination in duplicate performed by three analysts using 





Individual MeanA1 SDA1 CVA1 % MeanA2 SDA2 CVA2 % MeanA3 SDA3 CVA3 % MeanT SDT CVT %
P-09a HTLV-1 [L1] 5.36 1.30 0.03 2.18 1.55 0.04 2.29 1.36 0.02 1.57 1.40 0.12 8.37
P-14a HTLV-1 [L2] 6.54 1.42 0.04 2.50 1.58 0.01 0.45 1.41 0.08 6.02 1.47 0.09 6.38
P-19a HTLV 12.79 11.14 0.05 0.44 11.41 0.13 1.12 10.31 0.14 1.37 10.95 0.52 4,74
P-25b Negative 0.23 0.20 0.00 0.00 0.25 0.02 8.66 0.30 0.01 2.4 0.25 0.04 17.70
P-34a HTLV-2 [L1] 6.58 2.54 0.01 0.56 2.80 0.01 0.51 2.51 0.10 3.94 2.62 0.15 5.72
P-39a HTLV-2 [L2] 5.6 1.32 0.08 5.91 1.51 0.04 2.35 1.38 0.01 0.51 1.40 0.09 6.79
ID= Pool sera identification; OD/CO= optical density-to-cutoff ratio; SD= standard deviation; CV= coefficient of variation; L= low reagent sample by 
Murex; A1= results of analyst 1; A2 = results of analyst 2; A3 = results of analyst 3; T = total results. Pool composition, 
afour samples HIV/HBV/HCV/
HTLV-seronegative, bmix of one HIV-, one HBV-, and one HCV-positive samples plus one HIV/HBV/HCV/HTLV-negative sample. GraphPad Prism 
version 5.00 [Trial] software (GraphPad Software, San Diego, CA, USA) was employed by calculating the mean OD/CO, SD, and CV values.
Figure 3 - Costs of HTLV-1/2 antibody screening when conducted in individual serum samples and pool of five serum samples in 
American dollars (U$) in populations at risk in Brazil, using EIA Murex. EIA = enzyme immunoassay.
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individuals, as well as individuals with HTLV-1-associated 
diseases, is high but misdiagnosed1,4,5,21-24; thus, we decided 
to search for strategies that could reduce the cost of HTLV 
screening in this country to help the Ministry of Health 
of Brazil to introduce the serology of HTLV-1/2 in health 
care programs, especially in the national HTLV antenatal 
screening program. Using two EIAs commonly employed in 
screening in public health laboratories in Brazil, we tested 
the strategy of pooling sera, taking into account previous 
studies that demonstrated that pooling is feasible and cost-
effective mostly in populations with low prevalence of HIV 
and HTLV and/or in countries with limited resources12-15.
Both, EIA Murex and Gold ELISA were selected for 
analysis since their performances were recently well studied 
in two populations from different regions in Brazil. One 
study conducted in Sao Paulo (Southeast region) in 127 
HIV/Aids individuals pointed to the best performance of the 
Murex in relation to Gold ELISA. Murex detected higher 
titers (OD/CO values) of HTLV-1 and HTLV-2 antibodies 
when compared to Gold ELISA and showed more ability 
in detecting HTLV truly positive blood samples that were 
OD/CO non-reactive or borderline in Gold ELISA 
screening: two HTLV-2 and one HTLV untypeable samples 
confirmed by Western Blot and/or INNO-LIA and/or 
Polymerase Chain Reaction (PCR) assays25.
The other study conducted in individuals from blood 
banks seen at the HTLV outpatient clinic in Salvador 
(Northeastern Brazil) compared the performance of 
four screening assays: three EIA (including Murex 
and Gold ELISA) and one chemiluminescence assay 
(CMIA). Considering truly HTLV-positive (n=170) and 
HTLV-negative (n=200) samples by WB analysis, the best 
performance among assays was detected with Gold ELISA 
(100% sensitivity and >99.5% specificity) versus 100% 
sensitivity and 92.0% specificity (Murex)26. However, in 
the same study, when 27 blood samples were analyzed that 
yielded WB indeterminate results but confirmed HTLV-1 
infection by PCR, Murex showed more specificity and 
accuracy than Gold ELISA26. Indeed, when comparing 
the OD/CO values between the Murex and Gold ELISA, 
again the Murex presented the higher OD/CO values, which 
agrees with its use in pooling analysis. Thus, considering 
these recent studies and the results obtained previously 
by other groups outside Brazil with pooled samples14,15, 
the EIA Murex was chosen for use in the pool analysis. 
Serum samples from patients with HIV, HBV or HCV 
chosen to form the pools were employed to mimic these 
viruses coinfections that could occur in vivo and to ensure 
the lack of cross-reactivity of the pooling strategy. Of note, 
none of the samples truly HTLV-positive was lost using 
the pool of sera. The unique pool that was borderline on 
screening was stored for five days and was composed of a 
low HTLV-1 reactive sample. In any way, this sample was 
not missed because all the reactive and/or borderline (gray 
zone) samples would follow to the subsequent steps, which 
means, individual analyses and confirmatory assays. 
Since there is no universal guideline on the optimal 
way to perform validation/verification experiments of a 
new technique before being employed in the diagnostic 
laboratory, we used the guidelines established by the 
Instituto Adolfo Lutz, which employed qualitative and 
semi-quantitative analyses and the one that agrees with the 
guideline established for the clinical virology laboratory 
described elsewhere, which included explanation of 
statistical analysis and acceptance/rejection criteria18. For 
the precision analysis, we used the CV of less than 35% for 
acceptance18, although the results of CV obtained with the 
pooling of five samples and EIA Murex were much smaller 
than this value and were close to the values described in the 
manufacturer instructions of the EIA Murex HTLV-I+II, 
Diasorin, UK, CE-labeled (European Conformity) for 
single sample analysis (precision intra-assay CV varying 
from 4.3% to 9.3%, and inter-assay from 5.6% to 11.9%). 
Notably, the results of CV intra- and inter-assays obtained 
in the present study ranged from 6.46% to 16.13% and 
4.74% to 17.70%, respectively.
After validating the pooling strategy, to confirm the 
diagnostic sensitivity and specificity and cost minimization, 
the technique was employed in serum samples from HBV, 
HCV and HIV/AIDS patients previously tested individually 
for HTLV-1/2 antibodies19,20. The results obtained have 
confirmed the feasibility and reliability of the assay in 
sero-epidemiological surveys (Cohen’s Kappa = 1) and cost 
minimizations varying from 60.7% and 73.6%, depending 
on the HTLV-1/2 prevalence. The cost reduction was 
inversely proportional to the prevalence.
Although the present pooling technique was not tested 
in samples from pregnant women in Brazil, a recent study 
conducted in the United Kingdom (UK) using paired 
samples from 21 HTLV-1-infected women taken during 
pregnancy and while women were not pregnant showed 
that pregnancy does not impair the diagnosis of HTLV-1/2 
by either immunological (CMIA) or molecular (qPCR/
nPCR) tests27. Thus, we could suppose that the present pool 
of five sera using EIA Murex could also be employed in 
this population. Indeed, this strategy could be helpful for 
extending the HTLV diagnosis, since: (i) the number of 
HAM/TSP and ATL cases due to HTLV-1 mother-to-child 
transmission in Brazil has been underestimated21,22, (ii) the 
low number of HAM/TSP and ATLL cases described in this 
country could be due to the lack of or misdiagnosis rather 
than to the low incidence, (iii) the complexity of clinical 
Silva et al.
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manifestation and laboratory diagnosis of both diseases, (iv) 
the lack of knowledge in HTLV-1 and associated diseases 
among health professionals, (v) the difficult access to public 
health care in Brazil, especially in low-income areas, and 
(vi) the high morbidity/mortality of diseases21-24.
Of note, since 2002, pooling of sera has been employed 
in blood bank screening programs in the UK; they considered 
that pooling samples into a single sample reduces serological 
testing costs; therefore, fewer tests are required, initial and 
repeatedly reactive samples are reduced since the pooling 
dilutes low-level reactive samples (false-positive) and 
requires fewer confirmatory assays28. In December 2017, 
the UK National Screening Committee did not recommend 
the HTLV-1 testing in the antenatal screening program, but 
a recent study of the cost effectiveness conducted in the UK 
showed that screening of pooled samples in pregnant women 
is cost-effective in all analyzed scenarios29.
In conclusion, although the present study has limitations 
concerning the fact that only one EIA (Murex) was validated 
and no tests in pregnant women were conducted, the 
results obtained allow us to suggest the pooling strategy 
for the HTLV-1/2 national screening programs in Brazil. 
We recommend local laboratory analyses and validation 
using currently available commercial tests for HTLV-1/2 
screening, pointing out that if CMIA will be employed, 
probably more samples could be pooled, reducing even 
more the cost, since the signal-to-cut off (S/CO) values 
of this assay are higher than the OD/CO values of EIA, as 
previously described26.
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